epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

EPI-405, Phase III. Recruiting

A rare inherited neuromuscular disorder (genetically confirmed)

TSR-405 against placebo in an inherited neuromuscular disorder. Sponsor: Tailspin Rare Diseases (fictional), Rare disease.

Which sites are ahead, on target or behind their expectation, where each loses its patients, and what might help.

Sites at a glance

Data to September 30th 2026. Sponsor: Tailspin Rare Diseases (fictional). Study-level KPIs and QTLs have their own tabs: KPIs and QTLs.

Patients randomised

7 of 64

11% of the target

Sites open

18 of 18

Every planned site is open

Patients screened

20

Up: +5 in the last three months

Sites behind their expectation

None judged

Every site is too early to judge: fewer than two patients expected so far

Agreed, of patients approached

45%

55% in published cancer trials

Randomised, of patients screened

35%

The plan assumed 44%

Are enough patients being screened?

Over the last three months the study screened about two patients a month; since it began, 35% of patients screened have been randomised. Randomising the remaining 57 by the planned last patient in March 2027 takes about 33 screens a month, 19.5 times the recent pace. At the recent pace the target is more than two years beyond the planned date. That calls for a decision about the study, such as adding sites or countries, not site-by-site fixes.

Screening is behind the plan

Patients screenedCumulative, against the screens the plan implies: its expected randomisations divided by the 44% it expects to pass screening

Show data
Patients screened: planned and actual, by month
MonthPlannedActual
Sep 202400
Dec 202400
Mar 202500
Jun 202510
Sep 202542
Dec 2025107
Mar 20261713
Jun 20262414
Sep 20263218
Oct 20263420

Sources: epiClinical synthetic screening logs; screen failure by therapeutic area from the planner parameters (D23)

How each kind of site is doing

Each site is compared with what it was expected to recruit in its months open, given its type, track record, country and the protocol. Below 75% of that is behind; above 125% is ahead.

No site has been expected to recruit two patients yet, so none can be judged. Recruitment at this rate takes time to show.

Sites behind, and what might help

No site is behind its expectation.

Every site

Show all 18 sites
SiteProfileMonths openExpectedRandomisedApproachedScreenedPassed screeningStanding
405-US-01, SeattleSite new to research15.10.60310%Too early
405-US-02, ChicagoCommunity specialist practice17.60.7010–Too early
405-US-03, PhoenixCommunity specialist practice17.00.6010–Too early
405-US-04, Los AngelesAcademic medical centre13.20.70320%Too early
405-US-05, NashvilleSite new to research14.00.50110%Too early
405-US-06, DenverDedicated research centre18.91.6262100%Too early
405-UK-01, SheffieldRegional teaching hospital13.91.10320%Too early
405-UK-02, CardiffRegional teaching hospital14.11.1000–Too early
405-UK-03, LiverpoolRegional teaching hospital16.20.90320%Too early
405-UK-04, EdinburghRegional teaching hospital13.61.10210%Too early
405-ES-01, SevilleAcademic medical centre12.70.824367%Too early
405-ES-02, AlicanteSite new to research13.60.7040–Too early
405-ES-03, OviedoCommunity hospital13.91.1020–Too early
405-PL-01, OlsztynCommunity specialist practice11.20.80220%Too early
405-PL-02, KrakówSite new to research12.01.0020–Too early
405-TR-01, IstanbulAcademic medical centre14.70.5000–Too early
405-IN-01, LucknowSite new to research12.10.7232100%Too early
405-IN-02, ChennaiSite new to research16.40.714250%Too early

Rules behind this page

  • A site that has recruited below this share of its expected count is behind: 75%. epiClinical assumption, between the enrolment flag (0.8) and the point NCI trials rarely recovered from (0.6); about half of sites fall short of plan in practice (11% enrol nobody, 37% under-enrol; Tufts, register S-01).
  • A site that has recruited above this share of its expected count is ahead: 125%. epiClinical assumption, set symmetrically to the behind line on a ratio scale (1 ÷ 0.8).
  • Patients a site must have been expected to recruit before it is judged: 2. epiClinical assumption: below this, a site's count says more about chance than about the site.
  • Patients offered a trial who agree to take part: 55%. 55.0% of patients offered a cancer treatment trial agreed, across 35 studies (Unger 2021, JNCI, https://doi.org/10.1093/jnci/djaa155).
  • Patients needed at a funnel stage before a site's rate there is compared with the study's: 8. epiClinical assumption: with fewer, a single patient moves the rate by more than ten points.
  • A site's rate at a funnel stage is out of line when so poor a rate would happen by chance less often than this: 0.1. epiClinical assumption: a loose screen, because it prompts a look at the screening log rather than a judgement.
  • Patients fail screening: Screen failure is high and varies widely by therapeutic area (register PM-05); restrictive criteria are the commonest design barrier (PB-02, PD-01).
  • Patients wait too long for scans: epiClinical assumption from CRA practice; procedures per protocol rose 40.6% since 2010, which weighs on sites without services on site (register S-24).
  • Too little coordinator time: Coordinator turnover of 10 to 37% a year, rising to 35 to 61% in 2022; 45% of sites say capacity limits new studies (register S-09, S-11).
  • Competing trials take the same patients: Competing trials for the same patients reduce enrolment where the eligible pool is scarce (register EB-02, S-21).
  • Too few patients referred: Research-focused sites recruit about 41% better, but depend on referral routes (register S-07); referral networks lack outcome evidence (action A14).
  • Patients decline because of the journey: Procedural and visit burden lowers enrolment and retention (register PD-03); decentralised elements help mainly where travel is the barrier (PD-20).